We are live on
!
Find out more
SEC
Seven Eight Capital Portfolio holdings
AUM
$1.11B
1-Year Est. Return
29.48%
This Fund
S&P 500
This Quarter
Est. Return
-6.56%
1 Year Est. Return
+29.48%
3 Year Est. Return
+13.61%
5 Year Est. Return
+117.69%
10 Year Est. Return
+239.1%
AUM
$855M
AUM Growth
+$250M
(+41%)
Cap. Flow
+$327M
Cap. Flow
% of AUM
38.29%
Top 10 Holdings %
Top 10 Hldgs %
13.1%
Holding
788
New
316
Increased
155
Reduced
106
Closed
211
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edwards Lifesciences
EW
|
+$13.6M |
| 2 |
Merck
MRK
|
+$12.5M |
| 3 |
Intuitive Surgical
ISRG
|
+$11.1M |
| 4 |
DOCU
DocuSign
DOCU
|
+$10.9M |
| 5 |
Insulet
PODD
|
+$10.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nasdaq
NDAQ
|
+$7.26M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
+$6.86M |
| 3 |
Incyte
INCY
|
+$6.31M |
| 4 |
Fidelity National Information Services
FIS
|
+$5.73M |
| 5 |
AbbVie
ABBV
|
+$4.95M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.41% |
| 2 | Consumer Discretionary | 17.68% |
| 3 | Healthcare | 16.13% |
| 4 | Industrials | 12.13% |
| 5 | Financials | 8.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
SLM Corp
SLM
$5.24B
| $1.08M | 0.13% |
+79,556
| New | +$1.2M |
|
227
Johnson Controls International
JCI
$93.1B
| $1.08M | 0.13% |
20,336
-9,277
| -31% | -$572K |
|
228
ConocoPhillips
COP
$144B
| $1.08M | 0.13% |
+9,032
| New | +$1.05M |
|
229
Amazon
AMZN
$2.99T
| $1.08M | 0.13% |
+8,469
| New | +$1.13M |
|
230
Wabtec
WAB
$50.5B
| $1.07M | 0.13% |
10,105
+7,411
| +275% | +$825K |
|
231
TransUnion
TRU
$15.7B
| $1.07M | 0.13% |
14,933
+10,575
| +243% | +$829K |
|
232
Constellation Energy
CEG
$95.4B
| $1.07M | 0.13% |
9,820
-17,200
| -64% | -$1.77M |
|
233
NVR
NVR
$16.8B
| $1.07M | 0.12% |
+179
| New | +$1.11M |
|
234
News Corp Class B
NWS
$17.7B
| $1.06M | 0.12% |
+50,604
| New | +$1.05M |
|
235
AstraZeneca
AZN
$241B
| $1.06M | 0.12% |
7,797
+3,384
| +77% | +$462K |
|
236
Omnicom Group
OMC
$22.4B
| $1.05M | 0.12% |
14,137
+6,711
| +90% | +$553K |
|
237
ZTO Express
ZTO
$18.2B
| $1.03M | 0.12% |
+42,703
| New | +$1.09M |
|
238
Cinemark Holdings
CNK
$4.41B
| $1.03M | 0.12% |
+56,060
| New | +$939K |
|
239
Gentex
GNTX
$5.14B
| $1.03M | 0.12% |
+31,566
| New | +$1.01M |
|
240
monday.com
MNDY
$3.97B
| $1.02M | 0.12% |
+6,391
| New | +$1.07M |
|
241
BJs Wholesale Club
BJ
$12.3B
| $1.01M | 0.12% |
+14,216
| New | +$957K |
|
242
FIVE9
FIVN
$2.28B
| $1.01M | 0.12% |
+15,762
| New | +$1.18M |
|
243
Schrodinger
SDGR
$1.17B
| $1.01M | 0.12% |
+35,798
| New | +$1.44M |
|
244
McKesson
MCK
$97.2B
| $1.01M | 0.12% |
+2,313
| New | +$975K |
|
245
HDFC Bank
HDB
$123B
| $987K | 0.12% |
33,440
-4,526
| -12% | -$147K |
|
246
Sphere Entertainment
SPHR
$5.69B
| $980K | 0.11% |
+26,382
| New | +$972K |
|
247
Planet Fitness
PLNT
$4.43B
| $979K | 0.11% |
+19,909
| New | +$1.2M |
|
248
Blue Owl Capital
OBDC
$5.56B
| $977K | 0.11% |
+70,539
| New | +$974K |
|
249
Cincinnati Financial
CINF
$27.5B
| $976K | 0.11% |
9,537
+2,124
| +29% | +$222K |
|
250
Frontdoor
FTDR
$5.39B
| $975K | 0.11% |
+31,882
| New | +$1.06M |
|
Similar funds
PP
ECM
GCAC
CAM
D
GFS
FTIS
AIA
Seven Eight Capital's Q3 2023 Portfolio in Review
As of Q3 2023, Seven Eight Capital held 788 positions worth $855M, up 41% from $605M the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Seven Eight Capital deployed $327M of net new capital in Q3 2023, opening 316 new positions and adding to 155 existing holdings. Its largest new stake was Merck: 115,677 shares worth $11.9M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 22% a quarter earlier, followed by Consumer Discretionary and Healthcare.
On the sell side, the largest reduction was BioMarin Pharmaceuticals, an estimated $6.86M trimmed.
- Seven Eight Capital's largest Q3 2023 buy was Merck: 115,677 shares worth $11.9M.
- Seven Eight Capital added most to Edwards Lifesciences in Q3 2023, an estimated $13.6M increase.
- Seven Eight Capital's biggest Q3 2023 reduction was BioMarin Pharmaceuticals, cutting an estimated $6.86M.
- Seven Eight Capital fully exited Nasdaq in Q3 2023, selling an estimated $7.26M.
- Seven Eight Capital's ten largest holdings make up 13% of its $855M portfolio in Q3 2023.
- Seven Eight Capital opened 316 new positions and closed 211 in Q3 2023.
- Seven Eight Capital's portfolio value rose 41% quarter-over-quarter to $855M.
Based on Seven Eight Capital's 13F filing for Q3 2023, filed 14 Nov 2023.